BlackRock
ARTV

BlackRock’s Artiva Biotherapeutics ARTV Stock Holding History

BlackRock’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Buy
213,388
+850
+0.4% +$4.2K ﹤0.01% 4235
2025
Q4 		$912K Sell
212,538
-81,884
-28% -$309K ﹤0.01% 4328
2025
Q3 		$845K Sell
294,422
-191,305
-39% -$512K ﹤0.01% 4332
2025
Q2 		$733K Sell
485,727
-759,784
-61% -$1.6M ﹤0.01% 4352
2025
Q1 		$3.74M Buy
1,245,511
+199,158
+19% +$1.08M ﹤0.01% 3755
2024
Q4 		$10.5M Buy
1,046,353
+208,740
+25% +$2.51M ﹤0.01% 3399
2024
Q3 		$12.9M Buy
+837,613
New +$9.71M ﹤0.01% 3275

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock's ARTV Position: Q1 2026 in Review

BlackRock increased its Artiva Biotherapeutics (ARTV) stake by 0.4% in Q1 2026, buying an estimated $4.2K and bringing the position to 213,388 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4235.

BlackRock first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $12.9M in Q3 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • BlackRock held 213,388 shares of Artiva Biotherapeutics worth $1.37M as of Q1 2026.
  • BlackRock bought 850 Artiva Biotherapeutics shares in Q1 2026, an estimated $4.2K.
  • Artiva Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4235 holding.
  • BlackRock first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • BlackRock's Artiva Biotherapeutics position peaked at $12.9M in Q3 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.